The University of Kansas Medical Center and Hospital, 39th and Rainbow Blvd., Kansas City, KS 66106, USA.
Postgrad Med. 2010 Jan;122(1):198-200. doi: 10.3810/pgm.2010.01.2115.
Prasugrel was associated with a statistically significant reduction in rates of cardiac ischemic events in patients with ACS who had undergone PCI. Rates of post-PCI death from cardiovascular causes, nonfatal MI, or nonfatal stroke were also significantly reduced with the use of prasugrel versus clopidogrel. Major bleeding was significantly increased with the use of prasugrel versus clopidogrel. Mortality did not differ significantly between the groups.
普拉格雷可降低接受 PCI 的 ACS 患者的心脏缺血事件发生率，与氯吡格雷相比，其心血管原因导致的 PCI 后死亡、非致死性心肌梗死或非致死性卒中等发生率也显著降低。普拉格雷的使用与氯吡格雷相比，大出血显著增加。两组死亡率无显著差异。
